Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review.

Clicks: 342
ID: 97705
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #15 of 89 articles by views in Frontiers in endocrinology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Pituitary adenomas (PA) are amongst the most prevalent intracranial tumors, causing complications by hormonal overproduction or deficiency and tumor mass effects, with 95% of cases occurring sporadically. Associated germline mutations () and microduplications are increasingly identified, but the clinical consequences in sporadic PA remain unclear. This systematic review evaluates predictors of a genetic cause of sporadic PA and the consequences for treatment outcome. We undertook a sensitive MEDLINE/Pubmed, EMBASE, and Web of Science search with critical appraisal of identified studies. Thirty-seven studies on predictors of mutations and 10 studies on the influence on treatment outcome were included. and mutations were associated with young age of PA diagnosis. mutations were also associated with gigantism and macroadenomas at time of diagnosis. microduplications were associated with PA below the age of five. and mutation analysis is therefore recommended in young patients (≤30 years). mutation analysis is specifically recommended for patients with PA induced gigantism and macroadenoma. Screening for .3 microduplications is advisable in children below the age of five with increased growth velocity due to PA. There is no evidence supporting mutation analysis of other genes in sporadic PA. mutation related prolactinoma respond well to dopamine agonists while mutation associated somatotroph and lactotroph adenoma are frequently resistant to medical treatment. In patients harboring an microduplication treatment is challenging, although outcome is not different from other patients with PA induced gigantism. Effective use of genetic analysis may lead to early disease identification, while knowledge of the impact of germline mutations on susceptibility to various treatment modalities helps to determine therapeutic strategies, possibly lowering disease morbidity.
Reference Key
van-den-broek2019clinicalfrontiers Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors van den Broek, Medard F M;van Nesselrooij, Bernadette P M;Verrijn Stuart, Annemarie A;van Leeuwaarde, Rachel S;Valk, Gerlof D;
Journal Frontiers in endocrinology
Year 2019
DOI
10.3389/fendo.2019.00837
URL
Keywords
Screening mutation germline mutation pituitary adenoma genetic analysis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.